Marcia Simpson Brose, MD PhD
Marcia Simpson Brose, MD PhD
Assistant Professor of Otorhinolaryngology: Head and Neck Surgery at the Hospital of the University of Pennsylvania
Department: Otorhinolaryngology: Head and Neck Surgery
Graduate Group Affiliations
Contact information
Clinical Research Building (CRB), Room 127
415 Curie Blvd.
Philadelphia, PA 19104
415 Curie Blvd.
Philadelphia, PA 19104
Office: 215-615-6519
Fax: 215-573-1934
Lab: 215-898-0337
Fax: 215-573-1934
Lab: 215-898-0337
Email:
brosem@mail.med.upenn.edu
brosem@mail.med.upenn.edu
Publications
Links
Search PubMed for articles
Primary Work Website
Otorhinolaryngology Department Home Page
PUBMED link
Search PubMed for articles
Primary Work Website
Otorhinolaryngology Department Home Page
PUBMED link
Education:
B.A. (Biology)
Amherst College, Amherst, MA, 1986.
Ph.D. (Genetics and Developmental Biology)
Rockefeller University, New York, NY, 1994.
M.D. (Medicine)
Cornell University Medical College, New York, NY, 1995.
Permanent linkB.A. (Biology)
Amherst College, Amherst, MA, 1986.
Ph.D. (Genetics and Developmental Biology)
Rockefeller University, New York, NY, 1994.
M.D. (Medicine)
Cornell University Medical College, New York, NY, 1995.
Description of Research Expertise
Dr Brose runs a lab in the field of tranlsational studies in cancer genetics and genomics. Dr. Brose’s basic science research interest involves the identification of genetic abnormalities in the tumors of patients undergoing targeted therapies. She currently has projects underway in thyroid cancer, breast cancer, lung cancer, colon cancer and esophageal cancer. Once identified, she is interested in understanding if these changes may identify tumors that may have or lack resistance to certain compounds. She has experience in the use of mice, drosophila, human tissue culture and clincial tissue samples. Her analytic tools include all types of PCR, RT-PCR, as well as the use of array comparative genomic hybridization (aCGH) and transcription profiling, taqman analysis, Q-RT-PCR and DNA sequencing on a regular basis. She also uses high resolution expression and SNP genotyping tetchnologies (Affymetrix and Illumina) to study the genetic basis of cancer. Dr. Brose provides the key correlative science for ongoing phaseI/II/III clinical trials at the University and internationally.Description of Clinical Expertise
Familial cancer syndromes and cancer risk evaluation, PhaseI/II clinical trials, novel drug target discovery, and use of genetic testing in diagnosis, prognostication and treatment of cancer. Treatment of advanced thyroid cancer and cancers of the head and neck, lung and esophagus.Description of Other Expertise
Teaches residents and medical student who rotate through her lab in Hematology/Oncology and Cell geneticsSelected Publications
Lockhart*, A.C., Brose*, M.S., Kim*, E.S., Johnson, D.H., Peppercorn, J.F., Michels, D.L., Storm, C.D., Schuchter, L.M., and Rathmell*, W.K. (*Authors contributed equally to this work) : Physician and Stakeholder Perceptions of Conflict of Interest (COI) Policies in Oncology Journal of Clinical Oncology 31(13): 1677-1682, May (ePub Mar 25th) 2013.Brose, MS, Nutting, C, Jarzab, B, Elisei, R, Siena, S, Bastholt, L, de la Fouchardiere, C, Pacini, F, Paschke, R, Shong, YK, Sherman, SI, Smit, JWA, Chung, J, Siedentop, H, Molnar, I, Schlumberger, M: Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase 3 DECISION trial (Plenary Presentation). ASCO Annual Meeting, Abstract #4 May 2013.
Sherman, SI, Cohen, EW, Schöffski, P, Elisei, R, Schlumberger, M, Wirth, L Mangeshkar, M, Aftab, DT, Clary, DO, and Brose M: Efficacy of Cabozantinib (Cabo) in Medullary Thyroid Cancer (MTC) Patients with RAS or RET Mutations: Results from a Phase 3 Study (Oral Presentation). American Society of Clinical Oncololgy Annual Meeting May 2013.
Smallridge RC, Copland JA, Brose MS, Wadsworth JT, Houvras Y, Menefee ME, Bible KC, Shah MH, Gramza AW, Klopper JP, Marlow LA, Heckman MG, Von Roemeling R. : Efatutazone, an Oral PPAR-γ Agonist, in Combination with Paclitaxel in Anaplastic Thyroid Cancer: Results of a Multicenter Phase 1 Trial. J Clin Endocrinol Metab pending, April epub ahead of print 2013.
Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, Brose MS, Ellis LM, Erba H, George DJ, Gilbert MR, Jacobson JO, Larsen EC, Lichtman SM, Partridge AH, Patel JD, Quinn DI, Robison LL, von Roenn JH, Samlowski W, Schwartz GK, Vogelzang NJ. : Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol. Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. (eds.). 31(1): 131-161, January (Epub December 2012) 2013.
Elisei, R, Schlumberger, MJ., Mueller, S, Schöffski, P, Brose, MS, Shah, MH, Licitra, L, Jarzab, B, Medvedev, V, Kreissl, MC, Niederle, B, Cohen, EW, Wirth, LJ, Ali, H, Hessel, C, Yaron, Y, Ball, D, Nelkin, B, Sherman, SI: Cabozantinib in Progressive Medullary Thyroid Cancer. J Clin Oncol In press, 2013.
Brose MS.: In search of a real "targeted" therapy for thyroid cancer. Clin Cancer Res 18(7): 1827-1829, April [Epub 2012 Mar 26] 2012
Chu EY, Wanat KA, Miller CJ, Amaravadi RK, Fecher LA, Brose MS, McGettigan S, Giles LR, Schuchter LM, Seykora JT, Rosenbach M. : Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study. J Am Acad Dermatol. 67(6): 1265-1272, December (Epub May) 2012.
Brose, MS, Smit, J, Capdevila, J, Elisei,R, Nutting, C, Pitoia, F, Robinson, B, Schlumberger, M, Shong, YK, Takami, H.: Regional Approaches to the Management of Patients With Advanced, Radioactive Iodine (RAI)–Refractory Differentiated Thyroid Carcinoma. Endocrine Related Cancer Page: in press, September 2012.
Dong X, Tang W, Stopenski S, Brose MS, Korch C, Meinkoth JL. : RAP1GAP inhibits cytoskeletal remodeling and motility in thyroid cancer cells. Endocrine Related Cancer 19(4): 575-578, August 2012 Notes: Cover Art Provided by Laboratory of Marcia S Brose MD.